Alyeska Investment Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Alyeska Investment Group’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-608,604	Closed	-$402K	–	734
2024 Q2	$402K	Sell	608,604 -17,832	-3%	-$11.1K	﹤0.01%	510
2024 Q1	$377K	Hold	626,436	–	–	﹤0.01%	434
2023 Q4	$368K	Sell	626,436 -70,300	-10%	-$42.3K	﹤0.01%	451
2023 Q3	$464K	Buy	+696,736	New	+$854K	﹤0.01%	453
2020 Q3	–	Sell	-7,333	Closed	-$682K	–	611
2020 Q2	$682K	Buy	+7,333	New	+$404K	0.01%	422
2019 Q4	–	Sell	-52,787	Closed	-$746K	–	506
2019 Q3	$746K	Buy	+52,787	New	+$1.11M	0.01%	340

Alyeska Investment Group's VBIV Position: Q3 2024 in Review

Alyeska Investment Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 608,604 shares — an estimated $402K sold.

Alyeska Investment Group first reported a position in VBIV in Q3 2019 and held it in 6 quarters. The position peaked at $746K in Q3 2019. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

Alyeska Investment Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
Alyeska Investment Group sold 608,604 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $402K.
Alyeska Investment Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2019 and held it in 6 quarters.
Alyeska Investment Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $746K in Q3 2019.
1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.